Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia

Kim, Esther; McCormack, Paul L.

doi:10.1007/s40256-014-0099-7

Cited by 12 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Icosapent ethyl (Vascepa) is a high-purity EPA formulation containing >96% EPA ethyl ester, does not contain DHA, and is approved in the US to lower TG levels in adult patients with severe (≥ 500mg/dl) hypertriglyceridemia. 36 The ongoing REDUCE-IT trial has randomized patients at 470 centers worldwide, and aims to reveal if treatment for moderate TG elevation decreases CVD events, particularly among patients already receiving statin therapy.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review

Elagizi

Lavie²,

Marshall³

et al. 2018

Progress in Cardiovascular Diseases

View full text Add to dashboard Cite

The potential cardiovascular (CV) disease (CVD) benefits of Omega-3 Polyunsaturated Fatty Acids (OM3) have been intensely studied and debated for decades. Initial trials were performed in patients with low use of maximal medical therapy for CVD, and reported significant mortality benefits with the use of 1 g/day OM3 intervention following myocardial infarction (MI). More recent studies, including cohorts of patients receiving modern guideline directed medical therapy for CVD, have often not shown similar benefits with OM3 use. We conducted a literature review using PubMed, professional society guidelines, specific journal databases including New England Journal of Medicine and Journal of the American College of Cardiology from January 1, 2007 to December 31, 2017. References from selected articles were also reviewed, as well as key articles outside of the selected time-frame for their important findings or historical perspectives. Currently, there are no Class I recommendations from the American Heart Association (AHA) for the use of OM3, however, considering the safety of this therapy and beneficial findings of some modern studies (including patients with current maximal medical therapy for CVD), the AHA has recently expanded their list of Class II recommendations, in which treatment with OM3 for CVD benefit is reasonable. This review discusses the current state of the evidence, summarizes current professional recommendations, and provides recommendations for future research.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review

Elagizi

Lavie²,

Marshall³

et al. 2018

Progress in Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

“…17 In particular, DHA may increase LDL-C levels. 24,45,46 These differing actions may impact the efficacy of therapies meant to lower LDL-C levels. 17 IPE is a highly purified, stable ethyl ester of EPA.…”

Section: Pharmacology Of Ipementioning

confidence: 99%

“…17 IPE is a highly purified, stable ethyl ester of EPA. 18,45 Following oral administration, IPE is de-esterified to EPA before being absorbed in the small intestine. 18 The compound then enters the systemic circulation through the lymphatic system.…”

Section: Pharmacology Of Ipementioning

confidence: 99%

“…18 A linear dose-dependent relationship has been demonstrated with IPE and EPA levels; however, it does not impact DHA levels. 45,47 IPE has a mean volume of distribution of approximately 88 L at steady-state. 18 In all studies IPE was administered with or following a meal.…”

Section: Pharmacology Of Ipementioning

confidence: 99%

“…18,48 In addition to lowering TG levels, IPE has also been shown to have anti-inflammatory, anti-coagulant, and endothelial-and plaque-stabilizing pleiotropic effects, which may further explain the CV benefits seen with IPE therapy. 17,45,49 The recently completed REDUCE-IT EPA analysis evaluated patients in REDUCE-IT to examine EPA levels prior to randomization and during therapy for patients receiving IPE and placebo. 50 Serum EPA levels while on IPE therapy demonstrated a strong correlation with the primary composite endpoint of the study (CV death, MI, stroke, coronary revascularization, and unstable angina), the key secondary endpoint (CV death, MI, and stroke), as well as with the individual components of each endpoint.…”

Section: Pharmacology Of Ipementioning

confidence: 99%

See 2 more Smart Citations

Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists

Patel

Busch

2021

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Background: Atherosclerotic cardiovascular disease is a significant cause of morbidity and mortality worldwide. While use of statin therapy has improved management of lipids, an unmet need in reducing residual atherosclerotic cardiovascular disease risk and ischemic events persists. We provide an overview of the pharmacology of omega-3 fatty acids, omega-3 fatty acid cardiovascular outcomes trials, landmark clinical data and pharmacology of icosapent ethyl (a stable and highly purified ethyl ester of eicosapentaenoic acid), and the critical differences between fish oil supplements and prescription omega-3 fatty acids. Method: A PubMed literature review was conducted in April 2020 to identify articles discussing omega-3 fatty acid cardiovascular outcomes trials, pharmacology of icosapent ethyl, and the evaluation of fish oil dietary supplements and prescription omega-3 fatty acids. Results: Both eicosapentaenoic acid and docosahexaenoic acid have been widely associated with positive health benefits; however, data are inconsistent regarding the benefit of combination eicosapentaenoic acid and docosahexaenoic acid in patients with cardiovascular disease. Eicosapentaenoic acid, and specifically icosapent ethyl, has demonstrated atherosclerotic cardiovascular disease risk reduction among statin-treated patients. Important clinical differences exist between dietary supplement and prescription omega-3 fatty acid products. Conclusions: As research regarding the optimal management of dyslipidemia continues, additional therapy beyond statins is necessary to reduce atherosclerotic cardiovascular disease risk. In large cardiovascular outcomes trials, eicosapentaenoic acid has demonstrated cardiovascular benefit. Icosapent ethyl possesses a favorable efficacy and safety profile and should be considered as an adjunct to statin therapy to reduce ischemic event risk.

show abstract

Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease

Shibabaw

2020

Mol Cell Biochem

View full text Add to dashboard Cite

Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia

Cited by 12 publications

References 30 publications

Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review

Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review

Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists

Omega-3 polyunsaturated fatty acids: anti-inflammatory and anti-hypertriglyceridemia mechanisms in cardiovascular disease

Contact Info

Product

Resources

About